Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 14Esophageal Neoplasms 5Adenocarcinoma Of Esophagus 5Lung Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Sarcoma 3Rectal Neoplasms 3Colorectal Neoplasms 3Carcinoma, Intraductal, Noninfiltrating 3Squamous Cell Carcinoma of Head and Neck 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Osteosarcoma 2Multiple Myeloma 2Kidney Neoplasms 2Head and Neck Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Renal Cell 2Breast Carcinoma In Situ 2Vomiting 1Urologic Neoplasms 1Urogenital Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Teratoma 1Stomach Neoplasms 1Sarcoma, Alveolar Soft Part 1Rhabdomyosarcoma 1Prostate Adenocarcinoma 1Ovarian Neoplasms 1

Interventions

Gemcitabine 47Cisplatin 32pembrolizumab 28Paclitaxel 13Docetaxel 13avelumab 12Mitomycin 12atezolizumab 11Nivolumab 11Cystectomy 10Carboplatin 9durvalumab 7Sunitinib 7apaziquone 6Doxorubicin 6BCG Vaccine 65-aminolevulinic acid hexyl ester 6Vinblastine 5Radiation 5Platinum 5Methotrexate 5Magnetic Resonance Spectroscopy 5Albumin-Bound Paclitaxel 5Taxes 4Standard of Care 4Sorafenib 4Radiotherapy 4Fluorouracil 4Erlotinib Hydrochloride 41,2-diaminocyclohexaneplatinum II citrate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Urinary Bladder Neoplasms × Neoadjuvant Therapy × Clear all
NCT03636256 2023-08-14

Evaluation of NanoDoceĀ® in Participants With Urothelial Carcinoma

NanOlogy, LLC

Phase 1/2 Completed
36 enrolled 18 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urogenital Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔